Trump meets Zelenskiy, says Putin wants war to end, mulls trilateral talks
Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently sold 2,500 shares of the company’s common stock. The transaction, which took place on March 17, 2025, was executed at a price of $110.53 per share, totaling $276,325. The sale comes as Gilead, currently valued at $137.5 billion, trades near its 52-week high of $119.96, having delivered an impressive 59% return over the past year. According to InvestingPro analysis, the stock is currently fairly valued.
Following this sale, Dickinson retains ownership of 170,674 shares in the company. According to the filing, the transaction was conducted under a Rule 10b5-1 trading plan, which was adopted on August 29, 2024. The company maintains a "GOOD" financial health score according to InvestingPro, which offers 12 additional exclusive insights about Gilead’s financial outlook and market position in its comprehensive Pro Research Report.
In other recent news, Gilead Sciences reported high efficacy in its HIV and HBV treatment studies. New data from the 2025 Conference on Retroviruses and Opportunistic Infections highlighted impressive results from a Phase 3 study on Biktarvy, showing high rates of viral suppression in participants with HIV and HBV co-infection. Additionally, Gilead announced promising Phase 1 results for lenacapavir, an investigational drug for HIV prevention, which maintained effective plasma concentrations for over 56 weeks. In corporate developments, Gilead disclosed the departure of Sandra Patterson, its Senior Vice President, Corporate Controller, and Chief Accounting Officer, appointing Diane E. Wilfong as the interim replacement. Meanwhile, Bernstein analysts maintained an Outperform rating on Gilead, citing strong prospects for the company’s preventative HIV treatment, Len for PrEP. The analysts project a potential revenue peak of $5.7 billion by 2033 for this treatment. Furthermore, Gilead is closely monitoring potential federal funding cuts for HIV prevention efforts, as reported by the Wall Street Journal, which could impact the company’s operations in this sector. These developments underscore Gilead’s ongoing efforts in HIV treatment and prevention, as well as its adaptive strategies in the face of executive changes and funding uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.